

Haematologica
HAEMATOL/2018/194399
Version 3

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Christian Winther Eskelund, Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Rätty, Lone Bredo Pedersen, Christian Hartmann Geisler, Mats Jerkeman, and Kirsten Grønabæk

Disclosures: KG is on Celgene and Janssen advisory boards. MJ has received grants, personal fees and non-financial support from Janssen, grants and non-financial support from Celgene, during the conduct of the study; grants and non-financial support from Abbvie, grants, personal fees and non-financial support from Gilead, outside the submitted work. CG has received personal fees from Janssen. AK has received grants and personal fees from Nordic Nanovector, and grants from Roche and Merck. None of the other co-authors has any conflicts of interest to report.

Contributions: CWE performed genetic analyses. AA-L collected and analyzed the clinical data. CWE, AA-L, MJ and KG designed the genetic study and wrote the manuscript draft. AK, AL, RR, CHG and MJ conceived the clinical design. LBP purified DNA and performed MRD analyzes. All co-authors critically read and approved the final version of the manuscript.